欧洲抗风湿病联盟关于抗风湿药在备孕、妊娠和哺乳期使用的建议:2024年更新
欧洲抗风湿病联盟(EULAR)工作组按标准化操作流程更新了抗风湿药在备孕、妊娠、哺乳期及男性患者中使用的建议,提出5条总体原则和12条推荐。更新指出妊娠期可兼容的合成改善病情抗风湿药(DMARDs)包括抗疟药、硫唑嘌呤、秋水仙碱、环孢素、柳氮磺吡啶和他克莫司,并对妊娠期非甾体抗炎药(NSAIDs)和糖皮质激素的使用采取更严格的态度。
要点
- 妊娠期可兼容的合成DMARDs包括抗疟药、硫唑嘌呤、秋水仙碱、环孢素、柳氮磺吡啶和他克莫司。
- 基于个体化风险获益评估,所有肿瘤坏死因子抑制剂(TNFi)生物DMARDs可贯穿妊娠期使用,非TNFi生物DMARDs必要时可使用。
- 哺乳期可兼容药物包括抗疟药、硫唑嘌呤、秋水仙碱、环孢素、糖皮质激素、静脉注射免疫球蛋白(IVIG)、NSAIDs、柳氮磺吡啶和他克莫司,所有生物DMARDs被认为与母乳喂养兼容。
核心结论
- 更新后的建议提供共识性指导,将有助于改善患者在备孕、妊娠和哺乳阶段的照护质量。
研究设计与样本
- 依据EULAR标准化操作流程,由国际工作组确定系统文献综述的问题,随后制定更新后的声明。
- 对每条总体原则和声明采用预设的投票流程,并评定证据水平和推荐强度,参与者最终给出每条项目的同意程度。
主要发现
- 当前证据表明,妊娠期可兼容的合成DMARDs包括抗疟药、硫唑嘌呤、秋水仙碱、环孢素、柳氮磺吡啶和他克莫司。
- 关于NSAIDs和糖皮质激素,推荐在妊娠期对其使用采取更严格的态度。
- 基于个体化风险获益评估,所有TNFi生物DMARDs可贯穿妊娠期使用,非TNFi生物DMARDs必要时可使用。
- 关于哺乳期,可兼容药物包括抗疟药、硫唑嘌呤、秋水仙碱、环孢素、糖皮质激素、IVIG、NSAIDs、柳氮磺吡啶和他克莫司;所有生物DMARDs被认为与母乳喂养兼容。
- 关于男性用药,可兼容选择包括抗疟药、硫唑嘌呤、秋水仙碱、环孢素、IVIG、来氟米特、甲氨蝶呤、霉酚酸、NSAIDs、糖皮质激素、西地那非、柳氮磺吡啶、他克莫司和生物DMARDs。
关键数值与推荐
- 工作组提出5条总体原则和12条推荐,涉及妊娠前、妊娠期间、整个哺乳期以及男性患者中抗风湿药的使用。
- 妊娠期可兼容的合成DMARDs包括抗疟药、硫唑嘌呤、秋水仙碱、环孢素、柳氮磺吡啶和他克莫司。
- 推荐在妊娠期对NSAIDs和糖皮质激素的使用采取更严格的态度。
- 基于个体化风险获益评估,所有TNFi生物DMARDs可贯穿妊娠期使用,非TNFi生物DMARDs必要时可使用。
- 哺乳期可兼容药物包括抗疟药、硫唑嘌呤、秋水仙碱、环孢素、糖皮质激素、IVIG、NSAIDs、柳氮磺吡啶和他克莫司,所有生物DMARDs被认为与母乳喂养兼容。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To update the existing European Alliance of Associations for Rheumatology (EULAR) points to consider (PtC) for use of antirheumatic drugs in reproduction, pregnancy, and lactation, including additional drugs and adverse outcomes as well as paternal drug safety. METHODS: According to the EULAR standardised operating procedures, an international task force (TF) defined the questions for a systematic literature review, followed by formulation of the updated statements. A predefined voting process was applied to each overarching principle and statement. Level of evidence and strength of recommendation were assigned, and participants finally provided their level of agreement for each item. RESULTS: The TF proposes 5 overarching principles and 12 recommendations for the use of antirheumatic drugs before and during pregnancy, through lactation, and in male patients. The current evidence indicates that synthetic disease-modifying antirheumatic drugs (DMARDs) compatible with pregnancy include antimalarials, azathioprine, colchicine, cyclosporine, sulfasalazine, and tacrolimus. Regarding nonsteroidal anti-inflammatory drugs (NSAIDs) and glucocorticoids, a more restrictive approach to their use during pregnancy is recommended. Based on an individualised risk-benefit assessment, all tumour necrosis factor inhibitor (TNFi) biologic DMARDs (bDMARDs) can be used throughout pregnancy, and non-TNFi bDMARDs may be used if needed. In relation to lactation, compatible drugs include antimalarials, azathioprine, colchicine, cyclosporine, glucocorticoids, intravenous immunoglobulin (IVIG), NSAIDs, sulfasalazine, and tacrolimus. All bDMARDs are considered compatible with breastfeeding. Concerning the use of drugs in men, compatible options include antimalarials, azathioprine, colchicine, cyclosporine, IVIG, leflunomide, methotrexate, mycophenolate, NSAIDs, glucocorticoids, sildenafil, sulfasalazine, tacrolimus, and bDMARDs. CONCLUSIONS: The updated recommendations provide consensus guidance and will help to improve the quality of care of patients during the phases of reproduction, pregnancy, and lactation.
引用
- Rüegg L, Pluma A, Hamroun S, et al. EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update. Ann Rheum Dis. 2025. PMID: 40287311. doi:10.1016/j.ard.2025.02.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。